Senseonics®

Investor presentation

November 2025

Disclaimer

This presentation has been prepared by Senseonics Holdings, Inc. (the "Company," "Senseonics," "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Any statements in this presentation about future expectations, plans and prospects for Senseonics and its business, including statements , expectations for future financial or other performance, including projected revenue, gross margin, earnings and EBITDA growth, statements regarding plans, objectives and goals for future operations, statements about the future growth of Eversense® products, statements regarding planned initiatives, investments or marketing or other programs of Senseonics, statements regarding progress and timing of collaboration and rate of adoption or growth with respect to Eversense, or its patients and providers, or the potential to enhance patient outcomes, statements regarding increasing patient access, adoption and market share, and the future growth of the CGM market, statements regarding advancing development programs and potential regulatory events, approvals and availability and the attributes of future products, including launch timing of Gemini and Freedom, features and integrations, and other statements containing the words "believe," "expect," "intend," "may," "projects," "will," "planned" and similar expressions constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and projections about future events, and such statements are, by their nature subject to risk and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the negotiation and transition of the commercial responsibility for Eversense from Ascensia and the establishment of those functions at Senseonics, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration and roll-out of new technology and solutions, uncertainties inherent in finalizing integration and commercial terms and coordination with health systems and other new collaboration partners and third parties, uncertainties inherent in the ongoing commercialization of the Eversense product and the expansion of the Eversense product and Senseonics' and its partners' activities, uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2024 and the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, each as filed with the SEC, and Senseonics' other filings with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this presentation represent Senseonics' views as of the date hereof and the delivery of this presentation at any time shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. This presentation also presents management's goals and vision for Senseonics development programs, including without limitation the Gemini and Freedom development programs. These products are not approved by the FDA and are not subject to an IDE or other investigational approval. Plans, timing, specifications and other details of these programs are subject to change based on the factors above. The forward-looking statements in this presentation should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof.

About Eversense

The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.

One Year.
One CGM.
One Company.

Disruptive potential

One Company.

Focused strategy

Commercial momentum

Clear roadmap

Unlocking potential. Accelerating growth.

Investment highlights

Disruptive Potential
Addressing key patient pain points in a large, growing and underpenetrated CGM market

- ✓ $13.5bn global market size in 2025*
- ✓ #1 longevity and #1 survivability

Fully Integrated Capabilities
Unlocking operational efficiencies, commercial potential and financial benefits

- ✓ A new level of control and agility
- ✓ Topline accretion and margin expansion

Focused Strategy
Executing a clear growth strategy focused on awareness, access, scale and retention

- ✓ 2026 – an important year for execution
- ✓ Balance sheet supports investment

Commercial Momentum
Initiatives and investments are delivering results, validating our strategy and ambition

- ✓ 160% new patient growth in Q3 2025 over prior year
- ✓ 46% increase in Q3 2025 prescribers over prior year

Clear Roadmap
Building a sustainable financial profile and shaping the future of diabetes

- ✓ Goal to breakeven and profitability
- ✓ Robust pipeline: Gemini and Freedom

**Medtech Market Intelligence Report: CGM Market – Mass Device (October 2025).*

The CGM market is primed for growth and disruption

Large and growing market currently dominated by similar products with significant drawbacks

The market remains significantly **underpenetrated**

Significant **untapped opportunity** to expand market share and drive revenue growth

Senseonics is pioneering a completely new product category in long-term and fully-implantable CGMs

$13.5bn

2025 global CGM market*
(~20% CAGR to 2030)

38%

of eligible US patients utilize CGM**

Common CGM Frustrations

Sensor lifetime

Early failures

Accuracy issues

Wasted sensors

Skin irritation

Compression lows

Alarm fatigue

*Medtech Market Intelligence Report: CGM Market – Mass Device (October 2025)
**Market sizing sources on this slide are derived from sources on file at Senseonics

One Year. One CGM.

eversense 365
Continuous Glucose Monitoring System

The world's first and only One Year CGM system.



- Longest Lasting CGM
- Industry-Leading Survivability
- Exceptional Accuracy
- No More Wasted Sensors
- Minimal Skin Irritation
- Reduced compression lows

Gaining momentum…

160%

new patient growth in Q3 2025 the U.S. over the prior year

…by delivering value

Empowering **patients** with more autonomy, flexibility, and convenience

Enabling **HCPs** to make treatment decisions with greater clinical confidence

Product claims on this slide are derived from sources on file at Senseonics and user manuals of competitor products

One Company.

Unlocking potential and accelerating growth as a fully-integrated commercial organization.

Key benefits:

Unlocking operational efficiencies
Simplifying workflow and communication, freeing resource to drive strategy

Accelerating our commercial ambitions
A new level of control, agility and investment will support robust growth

Enhancing financial profile
Increased revenue share and better margins

New look. *Same Values.* *Enhanced Proposition.*

Key principles of the integration:

1. Maintain Momentum
2. Limit Disruption
3. Evolve Processes
4. Retain Best Talent
5. Enhance Team

Focused on Robust Growth

High conviction in our ability to deliver results through executing a focused commercial strategy.

Strategic priorities

1. Awareness
2. Access
3. Market Penetration
4. Retention

Key growth drivers

- Generate demand by driving patient (DTC) and HCP leads
- Grow inserter network and expand coverage
- Expand reach, commercial capacity and footprint
- Enhance the customer journey and experience

Growth Initiatives and Investments

We are focused on executing our strategy to unlock the potential of Eversense 365.

1 Awareness

DTC marketing

HCP marketing

Optimize targeting and product positioning

2 Access

Expand and optimize inserter network (inc. EON Care strategy)

Further expand coverage

Enhance Patient affordability

3 Penetration

Expand commercial team and capacity

Refocus approach to the European market

AID* market entry

4 Retention

Evolve onboarding process

Enhance user experience

Provide proactive support, with focus on renewals

Supported by improved operational control and financial firepower – up to $100m debt facility

Encouraged by recent commercial momentum and focused strategy

*Automated insulin delivery systems

EON *Care*: Expanding Access

A purpose-built subsidiary delivering mobile insertions to improve patient access nationwide

Extends reach to untapped patients

Enables prescriber-only physicians*

Boosts field-sales efficiency

Centralized scheduling & patient training

Reimbursable and self-funding

Our priorities:

1. Activate More Inserters

More than doubling the number of Eon providers in 2026

Future Growth Accelerators

- EON expansion of **50+ new providers** over next 12 months
- **Recruitment partner contracted** – acceleration well underway

2. Commercial Optimization

Leaning into EON for growth

SCALE: EON is <10% of all inserters but now **handles ~25% of insertions**

*Some HCPs prefer to prescribe only. EON Care enables all types of providers to offer Eversense access to their patients.

Early Execution and Momentum

Our commercial strategy is delivering results in 2025; a solid foundation to accelerate growth.

New Patient Growth



Inserter Growth



Prescriber Growth



Covered Lives



Addressing Patient Unmet Needs

Insights from patients and practitioners showcase product differentiation and real-life benefits.

90% of new patients now coming from competitors



I'll never go back to other CGMs Fits into
Best move I recommended it to my lifestyle
my HCP, now she's a prescriber
I've made Total game changer
Best CGM I've ever used
Accuracy Keeps getting better
is great Most reliable Removable for
So easy to manage convenience
No more adhesive Going on year 2
allergies Really decreases the burden

Building a Sustainable Financial Profile

Well-positioned to reach our target of long-term profitability.

Where we are today[1]

- **~$35M** FY2025 global revenues
- **35%-40%** gross profit margins
- Simplified capital structure
- Investment from large strategics

2026: Planned enhancements following resumption of commercialization of Eversense

- Topline accretion of at least 20%
- **15%-20%** gross profit margin expansion
- **Cash position** to fund near-term commercial investments

Goal: Future state as a fully-integrated business

- Sustainable earnings growth
- **70%+** gross profit margin
- EBITDA breakeven and profitability
- **Self-funded R&D** and development pipeline

Realizing near-term revenue. *Expanding topline growth.* *Achieving scale.*

1. Based on FY2025 guidance

Product Vision

Uniquely differentiated long-term technology solution with multiple product configurations with AID and Smart Pen integration

1

Sensor.

All patient segments.

No sensor changes for 1 year.

No transmitter.

No daily calibration.

GEMINI.

The first CGM with optional on-body transmitter

- Integrated 1-year battery
- Real-time CGM w/ transmitter; FGM* w/o transmitter
- For insulin and food decision making, as well as for AID

Designed for flexibility.

FREEDOM.

The first completely invisible CGM

- Integrated 1-year battery; no transmitter
- Direct Bluetooth communication between sensor and handheld
- For all intensively managed patients who want better control

Designed for FREEDOM.

**Flash Glucose Monitoring*

Program in development. Product attributes, specifications, and development timelines subject to risks and uncertainties.

The Journey Ahead

We have growth levers to pull and catalysts ahead. We are now in control of our own destiny.

2026

Senseonics

One Year. One CGM. One Company.
US commercial integration complete

Eversense 365 CE Mark Approval

European Market
Refocused approach and E365 launch

eversense 365 Continuous Glucose Monitoring System + twiist

First AID integration
twiist pump launch

Senseonics

One Year. One CGM. One Company.
OUS commercial integration complete

Gemini
Clinical & regulatory milestones
Clinical trial start and FDA submission

2027



Gemini – Launch
One-year sensor w/ battery for continuous & optional point-in-time reading

Freedom
Clinical & regulatory milestones
Clinical trial start and FDA submission

2028

Freedom – Launch
No transmitter – direct communication between sensor & handheld

Program in development. Product attributes, specifications, and development timelines subject to risks and uncertainties.

Shaping the Future of Diabetes

Continuing to push the boundaries in CGM. Innovating to improve the patient experience.

10 Years Ago

Short-term CGM

Traditional CGMs were an important step from BGM

Today

Long-term CGM

Eversense 365 is the cutting edge of innovation

Tomorrow

Invisible CGM

The future is no on-body transmitter – FREEDOM

Experienced Management Team

Timothy Goodnow

President & Chief Executive Officer

VERAX BIOMEDICAL
THERASENSE The Technology of Caring
Abbott Diabetes Care
DADE BEHRING
Baxter

Brian Hansen

Chief Commercial Officer*

TANDEM Diabetes Care
ASCENSIA Diabetes Care

Francine R. Kaufman

Chief Medical Officer

NDEP National Diabetes Education Program
American Diabetes Association.
Medtronic

Rick Sullivan

Chief Financial Officer

RoosterBio
HIKE FINANCIAL

Mukul Jain

Chief Operating Officer

Medtronic

One Year.
One CGM.
One Company.

Unlocking potential. Accelerating growth.

Thank you